Worldwide Clinical Trials
Worldwide Clinical Trials is recorded as a service provider in 104 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 104 trials · Latest update first
A Long-Term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants with Major Depressive Disorder (EMBRACE)
Sponsor Cybin IRL Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements
Sponsor Charm Therapeutics Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Sponsor Relay Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
Sponsor Immuneering Corp.
- Start (EU)
- Not reported
- Latest update
- Estimated end
The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Sponsor Inozyme Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer
Sponsor Acrivon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy
Sponsor Cns Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study operated at 47 centers in the United States, France, Italy, Spain, and Switzerland, with 58 investigators due to principal-investigator changes during the study.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Sponsor Dianthus Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical Allodynia
Sponsor Pharmnovo AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Sponsor GB002 Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC
Sponsor Triana Biomedicines Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Worldwide Clinical Trials?
The 2026-10-09 snapshot links Worldwide Clinical Trials to 104 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Project management, Data management, among 45 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Worldwide Clinical Trials?
The most frequently recorded therapeutic areas are Neurology, Genetic and Congenital Disorders, Musculoskeletal, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Worldwide Clinical Trials conducted?
The linked trials record locations in 24 countries, including Spain, Germany, Poland, Italy, France. These are trial locations, not confirmed office locations or countries where Worldwide Clinical Trials delivered services.
What can this page tell me about Worldwide Clinical Trials's trial experience?
Browse 104 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 6 recorded name variants under Worldwide Clinical Trials. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Worldwide Clinical Trials
- Worldwide Clinical Trials Early Phase Services LLC
- Worldwide Clinical Trials Holdings Inc.
- Worldwide Clinical Trials In Breve Wct S.r.l.
- Worldwide Clinical Trials Limited
- Worldwide Clinical Trials d.o.o.